These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 22097925)

  • 1. Investigational NMDA receptor modulators for depression.
    Szewczyk B; Pałucha-Poniewiera A; Poleszak E; Pilc A; Nowak G
    Expert Opin Investig Drugs; 2012 Jan; 21(1):91-102. PubMed ID: 22097925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NMDA antagonists under investigation for the treatment of major depressive disorder.
    Pochwat B; Pałucha-Poniewiera A; Szewczyk B; Pilc A; Nowak G
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1181-92. PubMed ID: 24818801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Ketamine for treatment of acute depression].
    Hjerrild S; Bjerre J; Pedersen RH; Videbech P
    Ugeskr Laeger; 2013 Sep; 175(37):2090-3. PubMed ID: 24011203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An update on NMDA antagonists in depression.
    Pochwat B; Nowak G; Szewczyk B
    Expert Rev Neurother; 2019 Nov; 19(11):1055-1067. PubMed ID: 31328587
    [No Abstract]   [Full Text] [Related]  

  • 5. [Lack of antidepresant-like activity of some ligands of polyamine binding sites of NMDA receptors in models of depression].
    Zin'kovskaia LIa; Kidin IuV; Komissarov IV; Obraztsova OG
    Eksp Klin Farmakol; 2006; 69(1):3-5. PubMed ID: 16579050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antidepressant effect of ketamine, a N-methyl-D-aspartate (NMDA) glutamate receptor antagonist, in the therapy of treatment-resistant depression].
    Gosek P; Chojnacka M; Bieńkowski P; Swiecicki Ł
    Psychiatr Pol; 2012; 46(2):283-94. PubMed ID: 23214398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test.
    Ghasemi M; Raza M; Dehpour AR
    J Psychopharmacol; 2010 Apr; 24(4):585-94. PubMed ID: 19351802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigational drugs for treating major depressive disorder.
    Dhir A
    Expert Opin Investig Drugs; 2017 Jan; 26(1):9-24. PubMed ID: 27960559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression.
    Koike H; Iijima M; Chaki S
    Behav Brain Res; 2011 Oct; 224(1):107-11. PubMed ID: 21669235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The involvement of glutamate in the pathophysiology of depression.
    Palucha A; Pilc A
    Drug News Perspect; 2005 May; 18(4):262-8. PubMed ID: 16034483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NMDA GluN2B receptors involved in the antidepressant effects of curcumin in the forced swim test.
    Zhang L; Xu T; Wang S; Yu L; Liu D; Zhan R; Yu SY
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():12-7. PubMed ID: 22960607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glutamate-based antidepressants: 20 years on.
    Skolnick P; Popik P; Trullas R
    Trends Pharmacol Sci; 2009 Nov; 30(11):563-9. PubMed ID: 19837463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dextromethorphan as a potential rapid-acting antidepressant.
    Lauterbach EC
    Med Hypotheses; 2011 May; 76(5):717-9. PubMed ID: 21367535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An extension of hypotheses regarding rapid-acting, treatment-refractory, and conventional antidepressant activity of dextromethorphan and dextrorphan.
    Lauterbach EC
    Med Hypotheses; 2012 Jun; 78(6):693-702. PubMed ID: 22401777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.
    Kishimoto T; Chawla JM; Hagi K; Zarate CA; Kane JM; Bauer M; Correll CU
    Psychol Med; 2016 May; 46(7):1459-72. PubMed ID: 26867988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low dose ketamine: a therapeutic and research tool to explore N-methyl-D-aspartate (NMDA) receptor-mediated plasticity in pain pathways.
    Chizh BA
    J Psychopharmacol; 2007 May; 21(3):259-71. PubMed ID: 17591654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective use of N-methyl-D-aspartate receptor antagonists as a spinoplegia against excitatory amino acid neurotoxicity.
    Cho Y; Ueda T; Mori A; Shimizu H; Haga Y; Yozu R
    J Vasc Surg; 2005 Oct; 42(4):765-71. PubMed ID: 16242566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of mTOR in depression and antidepressant responses.
    Abelaira HM; Réus GZ; Neotti MV; Quevedo J
    Life Sci; 2014 Apr; 101(1-2):10-4. PubMed ID: 24582593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glutamate-Based Drug Discovery for Novel Antidepressants.
    Pałucha-Poniewiera A; Pilc A
    Expert Opin Drug Discov; 2016 Sep; 11(9):873-83. PubMed ID: 27409299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting metabotropic glutamate receptors for rapid-acting antidepressant drug discovery.
    Musazzi L
    Expert Opin Drug Discov; 2021 Feb; 16(2):147-157. PubMed ID: 32962432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.